Why 2025 mattered: the “paper program” became real supply

Ukraine’s medical program shifted from legislative intent to operational reality in 2025. Two milestones signaled that the system was moving beyond frameworks:

• On June 2, 2025, Ukraine’s State Service of Ukraine on Medicines and Drugs Control (Derzhliksluzhba) publicly confirmed issuance of the first permit to import medical-use cannabinoid substances (a controlled category), a practical indicator that compliant cross-border sourcing was finally possible.
• By mid‑summer 2025, Ukraine’s Ministry of Health (MOH) announced it had expanded the list of available dosages for cannabinoid medicines within the national eHealth infrastructure, increasing prescriber and dispenser flexibility through the ePrescription workflow.

For operators—especially pharmacies, distributors, and importers—these steps created an urgent need for “readiness mapping”: aligning licensing, security, IT, dispensing protocols, and pharmacovigilance for controlled medicines.

This article is informational only and not legal advice.

External reference points (official):

• State Medicines Service (Derzhliksluzhba): https://www.dls.gov.ua/
• Ministry of Health of Ukraine: https://moz.gov.ua/
• eHealth system information (program overview): https://ehealth.gov.ua/
• State Expert Center (medicines registration and safety): https://www.dec.gov.ua/

Regulatory architecture in Ukraine: who does what

Ukraine’s medical market relies on several agencies with distinct roles. Understanding the handoffs is essential for cannabis compliance and for avoiding stalled imports or non-dispensable stock.

Key authorities

• MOH: health policy, clinical rules, eHealth governance, and implementation orders.
• Derzhliksluzhba (State Medicines Service): state control over medicinal products circulation; permits and control functions tied to controlled categories and inspections.
• State Expert Center (SEC): scientific evaluation support for medicinal product registration, safety monitoring coordination, and related regulatory science.
• Customs / border control: enforcement of import permit conditions for controlled goods.

Scheduling and controlled status

Ukraine treats these medicines as controlled (narcotic/psychotropic) category products. That status drives:

• import permit prerequisites
• heightened storage and security
• dispensing recordkeeping rules
• restricted handling to appropriately authorized entities

Pharmacies should assume controlled-substance level rigor (secure storage, inventory reconciliation, restricted access, audit-ready documentation) even when final implementing guidance continues evolving.

Import permits in 2025: practical pathway and what tends to slow it down

Ukraine’s first import permit (June 2, 2025) is widely interpreted as a “system test”: it demonstrates that the state’s paper-based rules can be applied to an actual shipment.

What an import-permit workflow generally requires

While exact document lists vary by product category and are shaped by Ukraine’s controlled-substance rules, importers should expect to align the following elements before applying:

• Controlled-substance handling authorization for the importing entity (and often for storage sites)
• GDP-aligned logistics plans, including temperature control if applicable
• GMP evidence for the manufacturing site (or equivalent proof recognized in Ukraine)
• Batch/lot documentation and quality certificates, with traceable chain of custody
• End-use justification and product destination details (licensed wholesaler/pharmacy network, where allowed)
• Security plan for storage and transport (restricted access, safes/vaults, alarms, documented procedures)

Operational bottlenecks to plan for

• Mismatch between permit scope and SKU reality: permit details must align precisely with the product form, strength, pack size, and intended use.
• Ukrainian labeling readiness: even when packaging is produced abroad, Ukraine-specific labeling and patient information expectations can delay release if not handled early.
• Pharmacy dispensability: importing a product that cannot be prescribed/dispensed through eHealth (missing recognized dosage entries, codes, or registration status) can trap inventory upstream.

Business takeaway

Treat import permitting as a cross-functional project involving regulatory affairs, quality, supply chain, and pharmacy-channel counterparts—because failure points often happen between functions.

Product registration and market access: why “importable” is not the same as “dispensable”

Import permits get products across the border; registration and eHealth configuration make products usable at the patient level.

Likely registration routes (what Ukraine typically uses)

Ukraine’s medicines system commonly uses a state registration model supported by SEC evaluation. Companies should plan for:

• dossier preparation (quality, safety, efficacy modules appropriate to the product)
• manufacturing site compliance evidence (GMP)
• Ukrainian-language labeling and leaflet readiness
• controlled category compliance embedded throughout (storage, distribution, dispensing restrictions)

Start here for official context:

• State Expert Center: https://www.dec.gov.ua/
• State Register/medicines regulatory context (entry point via MOH/SEC): https://moz.gov.ua/

The “eHealth bridge”

Even a registered medicine can face launch friction if it is not properly reflected in:

• ePrescription catalogs
• dosage/strength lists
• coding and reimbursement logic (if applicable in future policy)

The mid‑summer 2025 MOH move to expand dosage options in eHealth suggests regulators are actively tuning catalogs so prescribers can select clinically realistic strengths and forms.

Dosage forms prioritized in early rollout: what pharmacies should expect

Ukraine’s earliest phase has emphasized standardized medicinal forms rather than open-ended raw-material dispensing. In practical terms, the market tends to prioritize:

• oils/oral solutions with measurable concentrations (favored for titration and consistent dosing)
• capsules or other unit-dose oral formats
• potentially oromucosal sprays (where registered and supported)

Pharmacies should prepare for:

• multiple strengths per product family (the dosage expansion indicates regulators expect more options)
• titration counseling needs (start-low/go-slow protocols often used in clinical practice)
• heightened risk controls for look-alike strengths and substitution errors

Labeling in Ukrainian: readiness checklist for importers and pharmacies

Ukraine generally expects Ukrainian-language labeling and patient information for medicines placed on the market.

What to align before first shipments

• Outer packaging in Ukrainian (or legally acceptable over-labeling) with:
• product name
• strength/concentration
• dosage form
• batch/lot number
• expiry date
• storage conditions
• manufacturer/importer identifiers
• Patient leaflet in Ukrainian with dosing guidance, contraindications, and adverse reaction information
• Controlled status marking where required by Ukrainian controlled-medicine rules

Pharmacy execution risk

Even if importers handle over-labeling, pharmacies still need:

• SOPs for receipt verification (confirm the labeling matches invoices and registration)
• staff training to differentiate strengths and counsel correctly

Dispensing via ePrescription: pharmacy protocols tied to eHealth

Ukraine’s eHealth infrastructure is central to controlled-medicine dispensing because it supports:

• prescriber authentication and electronic signatures
• patient identification workflows
• prescription issuance and verification
• audit trails and reporting hooks

Official entry point: https://ehealth.gov.ua/

What “pharmacy readiness” means in practice

Pharmacies should build a controlled-dispensing protocol that covers:

• patient identity verification steps at pickup
• ePrescription validation (confirm prescriber, product, strength, quantity, and validity window)
• partial fills policy (whether allowed and how recorded)
• substitution rules (generally conservative for controlled medicines; confirm MOH guidance)
• counseling requirements (safe use, impairment cautions, storage at home)
• recordkeeping (inventory movement logs, reconciliation, discrepancy investigation)

IT integration: what to test before going live

Because the mid‑summer 2025 dosage expansion occurred inside eHealth, pharmacies should assume the catalog will continue to evolve. Your IT checklist should include:

• catalog sync: ensure your pharmacy management system pulls the latest SKU/dosage entries
• barcode/GS1 mapping (if used) to avoid manual entry errors
• role-based access: restrict controlled dispensing actions to authorized staff
• downtime procedures: define what happens if connectivity fails (including whether dispensing is paused)
• audit export: ability to export transaction logs for inspections

Timeline: a practical readiness map for 2025–2026

Below is a field-oriented timeline you can use to plan compliance workstreams. Adjust to your organization size and region.

Q2 2025 (what changed)

• June 2, 2025: first import permit issued by Derzhliksluzhba (operational supply signal)
• Early channel planning by importers/wholesalers begins in earnest

Q3 2025 (system tuning)

• MOH expands dosage entries in eHealth (mid‑summer 2025)
• Pharmacies begin validating that their dispensing software can:
• display new strengths
• select correct dosage forms
• transmit required transaction records

Q4 2025 (scale-up phase)

• Additional import permits and product launches likely increase
• Clinic onboarding becomes critical: providers must be configured and trained to prescribe through eHealth
• Distributor GDP and security audits become more frequent as volumes rise

2026 (expected consolidation)

• More stable product catalogs and prescribing norms
• Possible expansion of domestic manufacturing/processing pathways as regulations mature
• Stronger pharmacovigilance expectations as real-world use increases

Clinic onboarding and physician training: the hidden constraint

In many countries, supply is not the limiting factor—trained prescribers and configured clinics are.

Onboarding steps clinics should anticipate

• eHealth account and workflow configuration
• internal clinical protocols (patient selection, titration, follow-up cadence)
• controlled-medicine handling policies (sample management if any, storage if applicable)

Physician training priorities

• indication selection and when to consider cannabinoid therapies
• dose titration, adverse reaction recognition, and drug–drug interaction awareness
• documentation standards that support auditability

Business takeaway: pharmacies should coordinate with local prescribers early. A pharmacy can be fully compliant operationally but still see low throughput if clinicians are not issuing ePrescriptions correctly.

Domestic manufacturing and compounding: how it may phase in (2025–2026)

Ukraine’s near-term reality in 2025 was import-led. Over 2025–2026, stakeholders expect a gradual move toward domestic manufacturing or local finishing where regulations allow.

Likely staging pattern

• Stage 1: imports of finished dosage forms (simplest for quality control and standardized dosing)
• Stage 2: local packaging/secondary manufacturing (Ukrainian labeling and supply chain resilience)
• Stage 3: broader domestic production (requires clear licensing, security, and testing standards)

What pharmacies should watch

If local compounding is introduced (or expanded), pharmacies may face:

• new compounding standards and validation requirements
• tighter expectations for in-pharmacy QC and documentation
• inspection focus on raw material controls

Until regulators publish explicit compounding rules for these products, pharmacies should avoid assuming compounding will be broadly permitted.

Testing standards and quality gaps to flag (and how to mitigate now)

Ukraine’s system is still maturing. Regulators have signaled that details will continue to be clarified.

Where gaps often appear early

• testing standards: alignment on required panels (e.g., potency consistency, contaminants) and accepted methods
• batch release responsibilities: clarity on importer vs. manufacturer vs. local QP-equivalent roles
• stability and shelf-life expectations under Ukraine storage conditions

Mitigation actions for businesses

• contract only with suppliers that provide robust COAs and method references
• implement incoming QC verification (risk-based sampling where permitted)
• document a deviation process for out-of-spec findings and recalls

Pharmacovigilance: build it before volumes grow

As patient access expands, pharmacovigilance becomes both a safety requirement and a licensing risk.

Ukraine’s medicines safety ecosystem is centered on national pharmacovigilance processes, with SEC as a key institutional hub for safety information.

Start here: https://www.dec.gov.ua/

Pharmacy and distributor responsibilities to plan for

• capturing adverse event reports from patients
• routing reports to marketing authorization holders (MAHs) and appropriate national channels
• staff training to distinguish expected side effects vs. reportable events
• maintaining complaint logs and response timelines

Patient eligibility criteria: what’s clear, what’s still evolving

Ukraine’s clinical access rules are still being operationalized in practice. In early implementation phases, patient eligibility criteria can be:

• defined in MOH orders and clinical protocols
• constrained by which products/dosages exist in eHealth
• shaped by prescriber comfort and institutional policies

Practical guidance for pharmacies (informational)

• avoid “diagnosis guessing”—dispense strictly per ePrescription
• prepare patient education materials focused on safe use, storage, and follow-up
• coordinate with clinics on what documentation patients may need for continuity of care

Enforcement and inspections: what regulators typically look for first

In controlled-medicine rollouts, enforcement attention tends to focus on:

• storage security (safes, access logs, camera coverage where required)
• inventory reconciliation (counts, discrepancy investigations)
• ePrescription integrity (dispense-to-prescription match, no overrides)
• staff authorization and training records
• documentation (SOPs, incident reports, returns/destruction procedures)

Pharmacies that treat this as an IT project alone often fail on physical security and documentation—both are inspected.

Action checklist: pharmacy readiness map (do this now)

Governance and compliance

• appoint a controlled-medicines responsible person
• update SOPs for receipt, storage, dispensing, returns, and incident reporting

IT and workflow

• validate eHealth integration end-to-end in a test environment where possible
• implement role-based permissions and audit logging

Quality and safety

• create a pharmacovigilance intake script and escalation pathway
• train staff on strength differentiation and patient counseling

Partner alignment

• coordinate with importers/wholesalers on labeling approach and batch docs
• engage local clinics on prescribing workflows and patient follow-up expectations

Key takeaways

• Ukraine’s June 2, 2025 first import permit milestone marked the shift to real-world supply—and raised the bar for end-to-end cannabis compliance.
• The MOH’s mid‑summer 2025 dosage expansion inside eHealth signals active catalog tuning; pharmacies must keep IT and SOPs adaptable.
• “Importable” does not equal “dispensable.” Registration status, Ukrainian labeling, and ePrescription configurability determine commercial viability.
• The next risk frontier is pharmacovigilance, testing clarity, and patient eligibility rules—areas regulators often refine after initial launches.

Stay compliant as Ukraine’s rollout evolves

Ukraine’s dispensary rollout is pharmacy-led and tightly linked to eHealth. If you’re building an import strategy, onboarding clinics, or updating pharmacy SOPs for controlled medicines, use https://cannabisregulations.ai/ to monitor regulatory updates, map licensing obligations, and operationalize compliant dispensing workflows across your organization.